1. Home
  2. FNLC vs CBIO Comparison

FNLC vs CBIO Comparison

Compare FNLC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$29.26

Market Cap

306.9M

Sector

Finance

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$18.89

Market Cap

340.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
CBIO
Founded
1864
2003
Country
United States
United States
Employees
N/A
44
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
340.4M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FNLC
CBIO
Price
$29.26
$18.89
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
15.2K
219.7K
Earning Date
04-22-2026
05-23-2026
Dividend Yield
5.15%
N/A
EPS Growth
26.34
N/A
EPS
3.07
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$355.04
P/E Ratio
$9.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.11
$8.72
52 Week High
$30.33
$20.58

Technical Indicators

Market Signals
Indicator
FNLC
CBIO
Relative Strength Index (RSI) 56.94 77.93
Support Level $26.25 $10.89
Resistance Level $30.33 N/A
Average True Range (ATR) 0.71 1.57
MACD 0.13 0.79
Stochastic Oscillator 65.88 85.30

Price Performance

Historical Comparison
FNLC
CBIO

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: